354 related articles for article (PubMed ID: 33780288)
1. Mutations in
Fasching PA; Yadav S; Hu C; Wunderle M; Häberle L; Hart SN; Rübner M; Polley EC; Lee KY; Gnanaolivu RD; Hadji P; Hübner H; Tesch H; Ettl J; Overkamp F; Lux MP; Ekici AB; Volz B; Uhrig S; Lüftner D; Wallwiener M; Müller V; Belleville E; Untch M; Kolberg HC; Beckmann MW; Reis A; Hartmann A; Janni W; Wimberger P; Taran FA; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A; Hartkopf AD; Couch FJ
J Clin Oncol; 2021 May; 39(15):1619-1630. PubMed ID: 33780288
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of early-onset breast cancer based on BRCA1/2 mutation status in a French population-based cohort and review.
Bonadona V; Dussart-Moser S; Voirin N; Sinilnikova OM; Mignotte H; Mathevet P; Brémond A; Treilleux I; Martin A; Romestaing P; Raudrant D; Rudigoz RC; Lenoir GM; Lasset C
Breast Cancer Res Treat; 2007 Jan; 101(2):233-45. PubMed ID: 17061047
[TBL] [Abstract][Full Text] [Related]
3. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
[TBL] [Abstract][Full Text] [Related]
4. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations.
Bayraktar S; Gutierrez-Barrera AM; Lin H; Elsayegh N; Tasbas T; Litton JK; Ibrahim NK; Morrow PK; Green M; Valero V; Booser DJ; Hortobagyi GN; Arun BK
Clin Exp Metastasis; 2013 Jun; 30(5):631-42. PubMed ID: 23370825
[TBL] [Abstract][Full Text] [Related]
5. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients.
Wunderle M; Gass P; Häberle L; Flesch VM; Rauh C; Bani MR; Hack CC; Schrauder MG; Jud SM; Emons J; Erber R; Ekici AB; Hoyer J; Vasileiou G; Kraus C; Reis A; Hartmann A; Lux MP; Beckmann MW; Fasching PA; Hein A
Breast Cancer Res Treat; 2018 Aug; 171(1):85-94. PubMed ID: 29725888
[TBL] [Abstract][Full Text] [Related]
6. Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Kuchenbaecker KB; Neuhausen SL; Robson M; Barrowdale D; McGuffog L; Mulligan AM; Andrulis IL; Spurdle AB; Schmidt MK; Schmutzler RK; Engel C; Wappenschmidt B; Nevanlinna H; Thomassen M; Southey M; Radice P; Ramus SJ; Domchek SM; Nathanson KL; Lee A; Healey S; Nussbaum RL; Rebbeck TR; Arun BK; James P; Karlan BY; Lester J; Cass I; ; Terry MB; Daly MB; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; v O Hansen T; Ejlertsen B; Gerdes AM; Nielsen FC; Dennis J; Cunningham J; Hart S; Slager S; Osorio A; Benitez J; Duran M; Weitzel JN; Tafur I; Hander M; Peterlongo P; Manoukian S; Peissel B; Roversi G; Scuvera G; Bonanni B; Mariani P; Volorio S; Dolcetti R; Varesco L; Papi L; Tibiletti MG; Giannini G; Fostira F; Konstantopoulou I; Garber J; Hamann U; Donaldson A; Brewer C; Foo C; Evans DG; Frost D; Eccles D; ; Douglas F; Brady A; Cook J; Tischkowitz M; Adlard J; Barwell J; Ong KR; Walker L; Izatt L; Side LE; Kennedy MJ; Rogers MT; Porteous ME; Morrison PJ; Platte R; Eeles R; Davidson R; Hodgson S; Ellis S; Godwin AK; Rhiem K; Meindl A; Ditsch N; Arnold N; Plendl H; Niederacher D; Sutter C; Steinemann D; Bogdanova-Markov N; Kast K; Varon-Mateeva R; Wang-Gohrke S; Gehrig A; Markiefka B; Buecher B; Lefol C; Stoppa-Lyonnet D; Rouleau E; Prieur F; Damiola F; ; Barjhoux L; Faivre L; Longy M; Sevenet N; Sinilnikova OM; Mazoyer S; Bonadona V; Caux-Moncoutier V; Isaacs C; Van Maerken T; Claes K; Piedmonte M; Andrews L; Hays J; Rodriguez GC; Caldes T; de la Hoya M; Khan S; Hogervorst FB; Aalfs CM; de Lange JL; Meijers-Heijboer HE; van der Hout AH; Wijnen JT; van Roozendaal KE; Mensenkamp AR; van den Ouweland AM; van Deurzen CH; van der Luijt RB; ; Olah E; Diez O; Lazaro C; Blanco I; Teulé A; Menendez M; Jakubowska A; Lubinski J; Cybulski C; Gronwald J; Jaworska-Bieniek K; Durda K; Arason A; Maugard C; Soucy P; Montagna M; Agata S; Teixeira MR; ; Olswold C; Lindor N; Pankratz VS; Hallberg E; Wang X; Szabo CI; Vijai J; Jacobs L; Corines M; Lincoln A; Berger A; Fink-Retter A; Singer CF; Rappaport C; Kaulich DG; Pfeiler G; Tea MK; Phelan CM; Mai PL; Greene MH; Rennert G; Imyanitov EN; Glendon G; Toland AE; Bojesen A; Pedersen IS; Jensen UB; Caligo MA; Friedman E; Berger R; Laitman Y; Rantala J; Arver B; Loman N; Borg A; Ehrencrona H; Olopade OI; Simard J; Easton DF; Chenevix-Trench G; Offit K; Couch FJ; Antoniou AC;
Breast Cancer Res; 2014 Dec; 16(6):3416. PubMed ID: 25919761
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
[TBL] [Abstract][Full Text] [Related]
8. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
9. Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
Kolben T; Hary T; Holdt LM; Schwarz TM; Goess C; Wuerstlein R; Gallwas J; Toth B; Weissenbacher T; Jeschke U; Harbeck N; Ditsch N
Anticancer Res; 2016 Jun; 36(6):3185-90. PubMed ID: 27272846
[TBL] [Abstract][Full Text] [Related]
10. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
Bernstein-Molho R; Singer A; Laitman Y; Netzer I; Zalmanoviz S; Friedman E
Breast Cancer Res Treat; 2019 Jul; 176(1):165-170. PubMed ID: 30980208
[TBL] [Abstract][Full Text] [Related]
11. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
Tung N; Lin NU; Kidd J; Allen BA; Singh N; Wenstrup RJ; Hartman AR; Winer EP; Garber JE
J Clin Oncol; 2016 May; 34(13):1460-8. PubMed ID: 26976419
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.
Kuchenbaecker KB; McGuffog L; Barrowdale D; Lee A; Soucy P; Dennis J; Domchek SM; Robson M; Spurdle AB; Ramus SJ; Mavaddat N; Terry MB; Neuhausen SL; Schmutzler RK; Simard J; Pharoah PDP; Offit K; Couch FJ; Chenevix-Trench G; Easton DF; Antoniou AC
J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376175
[TBL] [Abstract][Full Text] [Related]
13. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
Rizzolo P; Zelli V; Silvestri V; Valentini V; Zanna I; Bianchi S; Masala G; Spinelli AM; Tibiletti MG; Russo A; Varesco L; Giannini G; Capalbo C; Calistri D; Cortesi L; Viel A; Bonanni B; Azzollini J; Manoukian S; Montagna M; Peterlongo P; Radice P; Palli D; Ottini L
Int J Cancer; 2019 Jul; 145(2):390-400. PubMed ID: 30613976
[TBL] [Abstract][Full Text] [Related]
14. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
[TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
17. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
[TBL] [Abstract][Full Text] [Related]
18. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
[TBL] [Abstract][Full Text] [Related]
19. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
Hamann U; Liu X; Bungardt N; Ulmer HU; Bastert G; Sinn HP
Eur J Hum Genet; 2003 Jun; 11(6):464-7. PubMed ID: 12774040
[TBL] [Abstract][Full Text] [Related]
20. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]